济南怎么让男人持久济南如何防止前列腺增生,济南早泄怎么治疗小窍门,济南阴茎上长了粒,济南治疗的阳痿,济南咨询男科专家,济南前前列腺炎症状,济南手术包茎的医院

BEIJING, Aug. 12 (Xinhuanet) -- Engineers at the University of Illinois have unveiled novel, skin-mounted electronics whose circuitry bends, wrinkles, and even stretches with skin, according to media reports quoting the Science Friday.The device platform includes electronic components, medical diagnostics, communications, and human-machine interfacing on a patch so thin and durable that it can be mounted to skin much like a temporary tattoo, the jounral described.What's more, the engineers demonstrated the invention across a wider range of components, including LEDs, transistors, wireless antennas, sensors, and conductive coils and solar cells for power."We threw everything in our bag of tricks onto that platform, and then added a few other new ideas on top of those to show that we could make it work," said engineering professor John A. Rogers in a news release.

PARIS, June 14 (Xinhua) -- Solar Impulse, a Swiss solar-powered aircraft, finally arrived in Paris on Tuesday after three days' delay, ready for a debut at the biennial International Paris Air Show.The 1.6-ton solar-powered plane was expected to land in Paris on Saturday but technical problems and bad weather forced it to turn back to Brussels.The plane took its first international flight from Switzerland to Brussels on May 13 and then marked its second international flight to Paris. It has 12,000 solar cells mounted on the wings, which provide momentum for its four electric motors.Solar Impulse is the first aeroplane designed to fly day and night without requiring fuel and without producing carbon emission. The 64-meter-wingspan (as wide as an Airbus A340) can fly at extremely slow speed and has a weight equivalent to that of an average family car.Regarded as a "special guest" in the show, Solar Impulse made a historic 26-hour day and night flight without fuel in July 2010.During the Paris air show from 20 to 26 June, visitors can enjoy a close look at the innovative plane on ground every day and if weather condition permits, flying displays will take place.According to Paris Air Show organizers, 59 of the top 100 companies in the air industry worldwide will be present. More than 1,800 small and medium-sized companies will be exhibiting their products during the one-week show. Enditem

SAN FRANCISCO, Aug. 15 (Xinhua) -- Facebook and Yahoo on Monday started to test "six degrees of separation," an iconic social experiment in the 1960s that showed everyone is on average approximately six steps away from any other person on earth.The current Facebook-Yahoo "small world" experiment, based on more than 750 million active Facebook users, is expected to determine the social path length between two strangers.Anyone with a Facebook account can participate by going to smallworld.sandbox.yahoo.com and will be assigned a "target person. " The participant will be asked to select one of his or her Facebook friends, whom will be forwarded a message and then pass the message from friend to friend so that the participant will get a message to the "target person" in as few steps as possible.The study is intended as academic social research and will be published in peer-reviews scientific journal, Duncan Watts, Yahoo' s principal research scientist who is leading the experiment, told San Jose Mercury News.In the 1960s, American social psychologist Stanley Milgram and other researchers conducted several experiments to examine the average path length for social networks of people in the United States, suggesting that human society is a small world type network by around 5.5 people steps or about six people on average.It is now currently accepted that there were potential flaws in the so-called "small world experiment" because the conclusions were based on relatively small number of research samples.

WELLINGTON, June 7 (Xinhua) -- Scientists in New Zealand have developed a new drug to fight previously untreatable hypoxic cancer tumors, which form in areas of the body starved of oxygen.The researchers at the Auckland University have entered an agreement for the clinical development of CEN-209, which was developed over 10 years of research, said a statement from the university Tuesday.CEN-209 was designed to enhance the effectiveness of radiotherapy and chemotherapy in solid hypoxic tumors, which were resistant to standard cancer therapies, said the statement. In lung cancer patients for example, about half of tumors had hypoxic regions.The new drug worked by damaging the DNA of hypoxic cancer cells, while leaving normal, healthy tissues alone.CEN-209 was designed and created by researchers at the university's Auckland Cancer Society Research Centre (ACSRC), using computer models of drug transport within tumors to accurately predict the anti-tumor activity of the drugs."Our computer models of drug transport developed in-house allowed the synthetic chemists to test their design theories and considerably shortened the discovery process," said Associate Professor Michael Hay, who led the ACSRC research chemists."CEN-209 improves markedly on previous agents in this class in terms of its ability to penetrate tumors, and this is reflected by its improved activity in the laboratory, when combined with long or short courses of radiotherapy," said researcher Professor Bill Wilson.Under the agreement between the university's Auckland UniServices Ltd. and California-based Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc., Centella will have exclusive rights to CEN-209, which it will develop and trial with Cancer Research UK.The work on CEN-209 is the culmination of a program initiated with funding from the U.S. National Cancer Institute, and more recently from the Maurice Wilkins Centre for Biodiscovery. Ongoing preclinical research on CEN-209 and a backup compound was funded by grants from the Auckland Medical Research Foundation, Genesis Oncology Trust and Health Research Council of New Zealand, said the statement.

STOCKHOLM, July 7 (Xinhua) -- A patient has been given a new trachea made from a synthetic scaffold seeded with his own stem cells in a Stockholm's hospital, the Swedish medical university Karolinska Institutet said on Thursday.The operation was performed on June 9th at Karolinska University Hospital in Huddinge and the patient, a 36-year old man, has been well on the way to recovery and would be discharged from the hospital on Friday, the university said in a statement.The patient had been suffering from late stage tracheal cancer with the tumor had reached approximately 6cm in length and was extending to the main bronchus.Since no suitable donor windpipe was available, the transplantation of the synthetic tissue engineered trachea was performed as the last possible option for the patient.The successful transplantation of tissue engineered synthetic organs, referred to as regenerative medicine, could open promising therapeutic possibilities for the thousands of patients who suffer from similar conditions.Transplantations of tissue engineered windpipes with synthetic scaffolds in combination with the patient's own stem cells as a standard procedure means that patients would not have to wait for a suitable donor organ.This would be a substantial benefit for patients since they could benefit from earlier surgery and have a greater chance of cure, according to the statement.